Postpartum hemorrhage (PPH) remains a leading emergency threatening maternal life. Clinically, Tranexamic Acid (TXA), owing to its unique antifibrinolytic properties, has become a cornerstone drug for obstetric hemostasis. However, cognitive biases regarding its timing, patient selection, dosage, and safety often lead to misuse, compromising efficacy and potentially increasing risks. This article addresses four core questions—When to use? Whom to give it to? How much to use? Is it safe?—integrating authoritative research findings to clarify misconceptions, outline standardized protocols, and provide a scientific reference for the rational use of TXA in obstetrics, ensuring both therapeutic efficacy and safety.

Pharmacological Basis: Why is TXA a Key Hemostatic Agent in Obstetrics?

Tranexamic Acid is a synthetic lysine analog and a specific antifibrinolytic agent. Its mechanism of action is clear and highly targeted: it competitively occupies the lysine-binding sites on plasminogen and plasmin, blocking the interaction between plasminogen and fibrin. This inhibits the excessive degradation of fibrin clots, stabilizes wound clots, and achieves rapid, controllable hemostasis.

Unlike uterotonics, TXA does not stimulate uterine contractions, alter uterine tone, or change placental blood flow. Therefore, it cannot replace first-line uterotonic drugs such as Oxytocin, Carboprost, or Ergometrine. Its role is that of a "Coagulation Stabilizer," not a "Contraction Booster." Establishing this core concept is critical for clinicians.

Pharmacokinetic Profile: Adaptability in Obstetric Emergencies

Rapid Onset: Takes effect within 10 minutes of intravenous administration, reaching peak plasma concentration in 30 minutes.

Optimal Half-life: Approximately 1.5–2 hours, matching the duration required for emergency management.

Excretion: Almost entirely excreted unchanged by the kidneys; it does not undergo hepatic metabolism, minimizing drug-drug interactions with commonly used obstetric medications.

Placental Transfer: Crosses the placenta with umbilical cord blood concentrations approaching maternal levels. Animal studies show no adverse fetal effects. However, human data during pregnancy are limited; strict adherence to indications is required, using TXA only when the benefits clearly outweigh the potential risks.

Low Protein Binding: Plasma protein binding is only 3%, allowing rapid distribution without increasing blood viscosity.

➱ Core Principle: The clinical efficacy of TXA depends on timing, not dosage; safety relies on standardized dosing and precise patient selection.

Treating Postpartum Hemorrhage: The Golden 3 Hours – Early Use Saves Lives

The value of TXA in obstetrics is most definitive and undisputed in the treatment of established PPH.

01 Top-Tier Evidence-Based Conclusions

(1) WOMAN Trial (Global Multicenter, >20,000 patients):

The results demonstrated that a single 1g IV dose of TXA:

Reduced the risk of death due to bleeding by 19% (RR=0.81).

When administered within 3 hours of delivery, the risk of death due to bleeding decreased significantly by 31%.

Significantly reduced the need for surgical interventions (laparotomy, compression sutures, arterial ligation) for refractory bleeding.

Showed no benefit if given after 3 hours, with a trend toward potential harm.

Benefited all modes of delivery (vaginal/C-section) and causes (atony, trauma, placenta).

Did not increase adverse events (thromboembolism, seizures, transfusion, hysterectomy) at treatment doses.

(2) Canadian Anesthesiologists' Society Review:

TXA is a time-dependent drug in obstetric hemorrhage. Every 15-minute delay reduces its benefit by approximately 10%.

(3) ISTH (International Society on Thrombosis and Haemostasis):

PPH is characterized by a hyperfibrinolytic state. Early antifibrinolytic therapy breaks the vicious cycle of "bleeding → fibrinolysis activation → further bleeding."

02 Clinical Standardized Protocol (Treatment)

Indication: Definite diagnosis of PPH (≥500 mL vaginal, ≥1000 mL cesarean).

Timing: Administer immediately upon diagnosis; strictly within 3 hours of delivery.

Dose: 1g TXA in 20 mL 0.9% NaCl, administered via slow IV push over ≥10 minutes.

Repeat Dose: If bleeding persists after 30 minutes or recurs within 24 hours, administer an additional 1g.

Maximum Daily Dose: Do not exceed 2g in 24 hours; avoid megadoses.

Combination Therapy: Must be used in addition to standard uterotonics; never as a standalone measure.

➱ Remember: Timing > Dosage. The earlier, the better.

Preventing Postpartum Hemorrhage: No Routine Use in Vaginal Delivery; Selective Use in High-Risk Cesarean Sections

This is a common area of clinical misconception. The 2025 Cochrane Systematic Review updates previous conclusions, clearly distinguishing strategies between vaginal delivery and cesarean section.

01 Vaginal Delivery: Not Recommended for Routine Prophylaxis

The Cochrane review strictly screened 3 large RCTs (total n=18,974) with high credibility, yielding clear conclusions:

Routine prophylactic 1g TXA after vaginal delivery showed no significant reduction in PPH ≥500 mL or severe PPH ≥1000 mL.

No reduction in transfusion rates, severe maternal morbidity, hysterectomy, or mortality.

Only a slight reduction in additional uterotonic use was seen in non-anemic women, lacking clinical significance.

Although rare, serious adverse events (thromboembolism, death, seizures) occurred with no offsetting benefit.

No clear benefit was observed in either low-risk or high-risk populations.

➱ Strong Recommendation: Do not routinely use TXA prophylactically after vaginal delivery.

02 Cesarean Section: Prophylactic Use Only in High-Risk Populations

Supported by the Canadian Anesthesiologists' Society and the ISTH Guidelines: Cesarean sections involve greater surgical trauma and higher bleeding risk, making prophylaxis beneficial for high-risk groups.

(1) High-Risk Populations Include:

Placenta previa, low-lying placenta, suspected placenta accreta/increta/percreta.

Multiple gestation, macrosomia, polyhydramnios.

Prolonged labor, risk of uterine atony.

History of PPH.

Moderate to severe antenatal anemia.

(2) Standard Prophylactic Protocol:

Timing: Immediately after fetal delivery and before placental delivery.

Dose: 1g slow IV push.

Combination: Concurrent with oxytocin to form "Uterotonic + Antifibrinolytic" dual protection.

Low-Risk C-section: Routine prophylaxis is not recommended.

➱ Consensus: No routine prevention for vaginal delivery; selective prevention for high-risk C-section only.

Safety Boundaries and Risk Management: Strict Contraindications

While generally safe, TXA requires clear clinical "red lines."

01 Absolute Contraindications

Known hypersensitivity to TXA or its excipients.

Active thromboembolic disease (DVT, PE, CVA, MI).

Disseminated Intravascular Coagulation (DIC) not anticoagulated.

Suspected or confirmed Amniotic Fluid Embolism with severe coagulopathy (unless anticoagulated).

02 Relative Precautions

Personal or family history of thrombosis (Thrombophilia).

Renal impairment (eGFR < 60 mL/min): Reduce dose by half or extend interval; monitor levels if necessary.

History of epilepsy: High doses may lower seizure threshold.

Concurrent use of estrogen or oral contraceptives.

03 Common Adverse Reactions & Management

Nausea/Vomiting/GI discomfort: Usually due to rapid injection; slow down the infusion rate.

Dizziness/Headache: Transient and mild; usually requires no specific treatment.

Visual disturbances: Extremely rare, only reported with long-term, supraphysiologic doses.

04 Key Safety Clarifications

Standard doses do not increase thrombotic risk.

Seizures are extremely rare in obstetrics (mostly reported in cardiac surgery with high doses).

Compatible with breastfeeding: Minimal secretion into breast milk; unlikely to affect healthy term neonates.

Clinical Essentials: 5 Rules Every Obstetrician Must Master

✿ Treatment is Primary, Prevention is Secondary: TXA's core value is treating PPH, not routine prevention.

✿ Respect the 3-Hour Golden Window: Delay renders the drug ineffective. Act fast.

✿ No Prophylaxis for Vaginal Delivery: Shift from blanket prevention to precise stratification (High-risk C-section only).

✿ Standard Dose is Enough: Blindly increasing dosage does not improve efficacy but increases risk.

✿ Never Replace Uterotonics: Uterotonics are the cornerstone; TXA is the "assist."

Conclusion

In the face of the ongoing threat of postpartum hemorrhage, Tranexamic Acid is not a universal hemostatic for all scenarios, but it is a vital obstetric tool that saves lives when used with the right timing and in the right patients. Let us rely on evidence-based medicine and standardized protocols to precisely utilize TXA, safeguarding the safe delivery of every mother.

References

[1] Rohwer C, Rohwer AC, Cluver C, et al. Tranexamic acid for preventing postpartum haemorrhage after vaginal birth. Cochrane Database of Systematic Reviews. 2025, Issue 1. Art.No.: CD007872. DOI: 10.1002/14651858.CD007872.pub4

[2] Wong, J., George, R.B., Hanley, C.M. et al. Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery. Can J Anesth/J Can Anesth68, 894–917 (2021). https://doi.org/10.1007/s12630-021-01967-7

[3] McQuilten Z, Wood E, Medcalf R. When to use tranexamic acid for the treatment of major bleeding? Journal of Thrombosis and Haemostasis, 2023; 22, 581-593.

Disclaimer: This article is based on three international references cited above. It is intended for medical professionals for academic exchange and should not be used as a sole basis for clinical practice. Clinical decisions must integrate individual patient conditions, institutional resources, and the latest guidelines. Multidisciplinary consultation is recommended when necessary.

Editor: Lily